Embed Size (px)
Citation preview
S rie de
gbpHsi
h
W
McDB
R∗
AéclasgcDtcdp(dppNdscmdetd
h
W
EaA
Z∗
AorsraGcCaWm(
ao
h
W
CjM
U∗
Tomwopoafecp
h
W
PdT
Z∗
Dortobotcmaptp
h
W
TaHa
Ub
c
U∗
306 IACAPAP 2012 – 20th World congress / Neuropsychiat
raphopathologie. Moins connu que les Bourneville, Jules Voisin, Sollier, Rou-inovitch, Dupré, décédé quelques mois avant l’ouverture du premier congrès desychiatrie de l’enfant (1937) qui s’est tenu à Paris sous les hospices de Georgeseuyer, Marcel Manheimer qui, à partir de 1918 se dénommait officiellement
ous le patronyme Marcel Gommès, fait parti de ces pionniers de la psychiatrienfantile francaise.
ttp://dx.doi.org/10.1016/j.neurenf.2012.04.889
e-P-3244
yopsychie dans un cas de dystrophie musculaireongénitale de type Ullrich. Tiberghien ∗, D. Bonnichon , S. Quijano-Roy , D. Leclair-Richard ,. Estournet-Mathiaud
Centre de référence des maladies neuromusculaire, hôpitalaymond-Poincaré, Garches, FranceAuteur correspondant.
u cours du xxe siècle et encore maintenant, une des préoccupations majeures até la constitution d’une nosographique des maladies neuromusculaires dont leadre nosologique s’est élargie du fait des progrès réguliers de l’histologie, de’histochimie, et la génétique, de la génétique moléculaire. Depuis le début desnnées 1980, les techniques de biologie moléculaire ont révolutionné la connais-ance des maladies neuromusculaires et permettent d’assigner une maladie à unène en particulier. Des retards intellectuels, des troubles cognitifs et ou psy-hiatrique ont été décrits dans les maladies neuromusculaires. Parmi celles-ci, laystrophie Musculaire Congénitale (DMC) de type Ullrich (DCMU) est carac-
érisée par un processus dystrophique lié à un déficit dans un des trois gènesodant le collagène VI, une des protéines constituant la matrice extracellulaireu muscle. Dans la DCMU, l’atteinte musculaire, précoce et de type dystro-hique comme dans toutes les DMC, prédomine au niveau des muscles du troncmusculature axiale). Ceux-ci sont touchés plus précocement que les muscleses membres supérieurs ou inférieurs. Il existe une nette tendance à dévelop-er des rétractions. Elle n’est pas ou peu évolutive. Aucun trouble cognitif ousychiatrique n’a jusqu’alors été rapporté dans cette entité.ous rapportons, ici, l’observation d’un garcon de 12 ans 6 mois présentant uneysharmonie évolutive de structure psychotique et qui, a l’âge de 13 mois a pré-enté un retard des acquisitions motrices. À 24 mois, une biopsie musculaire aonfirmé le diagnostic de DMCU. L’IRM cérébrale était normale. Dès les pre-ières années de vie des indices psychopathologiques étaient déjà présent. Nous
iscuterons de la place des troubles psychiques au sein de cette maladie génétiquet soulignerons qu’à côté de la surveillance orthopédique, cardiaque, respira-oire, la surveillance de l’état psychique doit faire partie de la prise en chargees maladies neuromusculaires dans le cadre de consultation pluridisciplinaire.
ttp://dx.doi.org/10.1016/j.neurenf.2012.04.890
e-P-3245
scitalopram and quality of life in older adolescents withnxious and depressive symptoms. Tomac ∗, T. Jakovina , S. Strbe , A. Razic
Department of Psychological Medicine, University Hospital Center Zagreb,agreb, CroatiaCorresponding author.
nxiety and depressive symptoms are the most common mental symptomsccurring during adolescence. According to the literature and clinical expe-ience untreated symptoms tend to extend to adulthood, which generates aerious public health issue. Despite high prevalence, these symptoms are rarelyecognized for various reasons. Cipralex (escitalopram, Lundbeck S/A, SSRIntidepressant) is present in Croatia since 2002 in adults, indications: MDD,AD, panic disorder w/o agoraphobia, social anxiety disorder and obsessive
ompulsive disorder. Aim of this naturalistic study was getting insight intoipralex influence on quality of life (QoL) among adolescents with anxiety
nd depressive symptoms.e followed 20 adolescents, 18–21 years, who begun their psychiatric treat-ent at our Department. QoL was assessed with WHO quality of life scaleWHOQOL-BREF), on two occasions–before taking first dose of Cipralex, and
Thct
l’enfance et de l’adolescence 60S (2012) S254–S309
fter three months of regular usage. Preliminary results suggest improved qualityf life and overall functioning in adolescents taking Cipralex.
ttp://dx.doi.org/10.1016/j.neurenf.2012.04.891
e-P-3246
omparing the criminal careers of female and maleuvenile offenders from adolescence to middle age.A. Forti-Buratti ∗, T. Kramer
Academic Unit of Child and Adolescent Psychiatry, Imperial College, London,K
Corresponding author.
he aim of this study is to compare the 30-year criminal career characteristicsf early (10- to 12-year-old) versus late (15- to 17-year-old) onset of female andale juvenile offenders. A cohort of 3636 juvenile offenders from Jan-Mar 1980as identified from the Offenders Index with their subsequent 30-year historyf offending. The criminal career of each individual was divided into four ageeriods and within each age period the total number of twelve different types offfending was recorded. The sub-groups were compared according to frequencynd versatility of offending over time. We also calculated the severity-weightedrequency and versatility of each group for the whole criminal career and forach of the age-periods. Analysis of the similarities and differences in criminalareer characteristics on the basis of gender and age at first conviction will beresented. Clinical implications will be discussed.
ttp://dx.doi.org/10.1016/j.neurenf.2012.04.892
e-P-3247
arental cardiovascular diseases as a risk factor forevelopment of mental health problems in their children. Jakovina ∗, A. Tomac , A. Kordic , D. De Zan
Department of Psychological Medicine, University Hospital Centre Zagreb,agreb, CroatiaCorresponding author.
uring 2009, in Croatia, 25,976 people died (49.6% overall mortality) as a resultf cardiovascular diseases (CAD), what is in accordance with WHO data, andepresents a major public health problem. Clinical experience suggests the exis-ence of mental disorders in children and adolescents whose parents are sufferingf CAD. These children usually ask for help when their psychological distur-ances have already become chronicle. Prevention, treatment and rehabilitationf CAD are primarily focused on the biomedical approach, but it is necessaryo bear in mind the psychological superstructure and emotional disturbances inhildren of suffering parents. Specific developmental characteristics and dyna-ics of childhood and adolescence can be modified by parental illness, with an
dverse effect on normal development and functioning (neurotic identification,arentification, separation anxiety). Considering all this, we suggest that all par-icipants in the rehabilitation process of CAD should be acquainted with thishenomenon, what would enable the prevention or early intervention.
ttp://dx.doi.org/10.1016/j.neurenf.2012.04.893
e-P-3248
he WHO EMR atlas: Country resources for child,dolescent and maternal mental health in the EMR. Hamoda a,∗, K. Saeed b, C. Servili b, H. Madi b, M. Belfer c
Psychiatry, Children’s Hospital Boston, Harvard Medical School, Boston,SAWHO EMRO, Cairo, EgyptDepartment of Psychiatry: Fegan 8, The Children’s Hospital Boston, Boston,SA
Corresponding author.
he development of policies and programs for child and adolescent mentalealth clearly lag behind those for adult mental health. We present a studyonducted by the WHO EMRO in collaboration with Children’s Hospital Bostono map child, adolescent and maternal mental health services in the Eastern
